Last reviewed · How we verify

NCT04651972: DIADAUVEDA

Measurement of vanilloïd Compounds in Urin of Autistic vs Control Patients, as Potential Biomarkers

Status unknown Last updated 3 December 2020
What this trial tests

trial in Autism Spectrum Disorder in 140 participants. Status unknown.

Timeline
15 December 2020
Primary endpoint
30 July 2022
30 July 2022

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment140
Start date15 December 2020
Primary completion30 July 2022
Estimated completion30 July 2022

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

Adults 2 to 14, male only, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In a former study, four vanilloid compounds were observed increased in the urin of autistic patients. The present study is aimed at performing a ambispective study to confirm or not these preliminary results. 70 urins from autistic children (already collected) will be compared to 70 urins of non autistic children (collected without intervention, remaining sample from the standard care), in terms of measurements of four vanilloid compounds using a GCMS apparatus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04651972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing